Bitte einloggen
Sie müssen angemeldet sein, um die Kontaktanfrage zu senden.
Standverwaltung
Option auswählen
Fluxergy, Inc.
13766, Alton Parkway Suite 150,
92618
Irvine, CA
USA
USA
Kontaktdaten an Aussteller übermitteln
Übermitteln Sie dem Aussteller Ihre Kontaktdaten. Optional können Sie eine persönliche Nachricht ergänzen.
Gegenstand der Übermittlung personenbezogener Daten sind Ihr Name, Ihre Telefonnummer und Ihre E-Mail Adresse. Die Messe Düsseldorf GmbH weist ausdrücklich darauf hin, dass für die Übermittlung personenbezogener Daten in Drittländer, für die kein Angemessenheitsbeschluss der EU-Kommission vorliegt, der ein angemessenes Datenschutzniveau attestiert, nicht sichergestellt ist, dass geeignete Garantien für den Schutz personenbezogener bestehen.
Ein Fehler ist aufgetreten
Bitte überprüfen Sie Ihre Internetverbindung oder versuchen Sie es zu einem späteren Zeitpunkt noch einmal.
Nachricht erfolgreich gesendet
Ihre Nachricht an den Aussteller wurde erfolgreich gesendet.
Mediendateien des Ausstellers
Ansprechpartner
Dr. Ali Tinazli
Chief Commercial Officer
Besuchen Sie uns!
16.11.2020
Thema
ganztägig
Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*
The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
ganztägig
How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing
The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
17.11.2020
Thema
ganztägig
Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*
The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
ganztägig
How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing
The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
18.11.2020
Thema
ganztägig
Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*
The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
ganztägig
How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing
The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
19.11.2020
Thema
ganztägig
Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*
The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
ganztägig
How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing
The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Unser Angebot
Produktkategorien
- 03 Diagnostika
- 03.01 Klinische Chemie
- 03.01.03 Harndiagnostik, Geräte und Systeme für die
Harndiagnostik, Geräte und Systeme für die
- 03 Diagnostika
- 03.01 Klinische Chemie
- 03.01.04 Schnelltests in der klinischen Chemie
Schnelltests in der klinischen Chemie
- 03 Diagnostika
- 03.02 Immunochemie / Immunologie
- 03.02.01 Immun-Assay-Systeme
Immun-Assay-Systeme
- 03 Diagnostika
- 03.02 Immunochemie / Immunologie
- 03.02.02 Diagnose-Schnelltests
Diagnose-Schnelltests
- 03 Diagnostika
- 03.03 Hämatologie / Histologie / Zytologie
- 03.03.04 Sonstige Geräte und Tests zur Hämatologie / Histologie / Zytologie
Sonstige Geräte und Tests zur Hämatologie / Histologie / Zytologie
- 03 Diagnostika
- 03.04 Mikrobiologie-Tests
- 03.04.03 Schnelltests in der Mikrobiologie
Schnelltests in der Mikrobiologie
- 03 Diagnostika
- 03.05 Infektionsimmunologie
- 03.05.02 Mikrobiologische Diagnostik / Virologie, Geräte und Systeme für die
Mikrobiologische Diagnostik / Virologie, Geräte und Systeme für die
- 03 Diagnostika
- 03.06 Gentests, molekularbiologische Diagnostik
- 03.06.01 DNA-Tests
- 03 Diagnostika
- 03.06 Gentests, molekularbiologische Diagnostik
- 03.06.02 Molekulare Biomarker
Molekulare Biomarker
- 03 Diagnostika
- 03.06 Gentests, molekularbiologische Diagnostik
- 03.06.03 Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR)
- 06 Informationstechnik und Kommunikationstechnik
- 06.02 mHealth, mobile IT, kabellose Technologien (wireless, Bluetooth, W-LAN)
mHealth, mobile IT, kabellose Technologien (wireless, Bluetooth, W-LAN)
- 06 Informationstechnik und Kommunikationstechnik
- 06.04 eHealth, Telemedizin / Telematik / Telemetrie
eHealth, Telemedizin / Telematik / Telemetrie
Unsere Produkte
Produktkategorie: Diagnose-Schnelltests, Schnelltests in der Mikrobiologie, Polymerase chain reaction (PCR), Mikrobiologische Diagnostik / Virologie, Geräte und Systeme für die, DNA-Tests, Molekulare Biomarker, mHealth, mobile IT, kabellose Technologien (wireless, Bluetooth, W-LAN), eHealth, Telemedizin / Telematik / Telemetrie
Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*
The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities
are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future evenets could differ materially from those anticipated in such statements.
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities
are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future evenets could differ materially from those anticipated in such statements.
Produktkategorie: Polymerase chain reaction (PCR), Diagnose-Schnelltests, Harndiagnostik, Geräte und Systeme für die, Schnelltests in der klinischen Chemie, Immun-Assay-Systeme, Sonstige Geräte und Tests zur Hämatologie / Histologie / Zytologie, Schnelltests in der Mikrobiologie, Mikrobiologische Diagnostik / Virologie, Geräte und Systeme für die, DNA-Tests, Molekulare Biomarker, mHealth, mobile IT, kabellose Technologien (wireless, Bluetooth, W-LAN), eHealth, Telemedizin / Telematik / Telemetrie
Fluxergy Analyzer Platform*
Our core device, the Fluxergy Analyzer, is a highly-integrated sensor system along with our sophisticated analysis algorithms. The Fluxergy Analyzer can be used for laboratory analyses such as PCR, ELISA, ISE, and cytometry-based assays.
Ruggedized Exterior Casing
The Fluxergy Analyzer features a smooth monocoque casing that is both lightweight and robust.
Active Cooling System
The active cooling system allows the Fluxergy Analyzer to rapidly manipulate the subjected sample to significantly decrease test times.
Quick Battery Hookup
Whether you are in a resource-limited setting or at a high-tech laboratory, the Fluxergy Analyzer can always have power. Simply hook up a compatible battery pack and realize the portability of the Fluxergy Analyzer system.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities
are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future evenets could differ materially from those anticipated in such statements.
Ruggedized Exterior Casing
The Fluxergy Analyzer features a smooth monocoque casing that is both lightweight and robust.
Active Cooling System
The active cooling system allows the Fluxergy Analyzer to rapidly manipulate the subjected sample to significantly decrease test times.
Quick Battery Hookup
Whether you are in a resource-limited setting or at a high-tech laboratory, the Fluxergy Analyzer can always have power. Simply hook up a compatible battery pack and realize the portability of the Fluxergy Analyzer system.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities
are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future evenets could differ materially from those anticipated in such statements.
Firmennews
Über uns
Firmenporträt
Das 2013 gegründete Unternehmen Fluxergy hat sich zum Ziel gesetzt, eine tragbare, einfach zu bedienende Probe-zu-Antwort-Plattform bereitzustellen, die es Klinikern ermöglicht, eine breite Palette anspruchsvoller Multiplex- und multimodaler In-vitro-Diagnosetests (verschiedene Testarten auf einmal, bis zu 30 Ziele) am Point-of-Care kostengünstig durchzuführen.
Das Fluxergy-Diagnosetestsystem besteht aus der Fluxergy Card, einer Einweg-Lab-on-Chip"-Testkassette für Verbrauchsmaterial; dem Fluxergy Analyzer, der den Testprozess durchführt, und der FluxergyWorks-Software, die vom Kliniker/Bediener zur Überprüfung und Interpretation der Testdaten verwendet wird. Die Fluxergy-Karten sind so konzipiert, dass sie sehr kosteneffektiv und skalierbar sind, wobei proprietäre Technologien zur Herstellung von Leiterplatten (PCB) und Mikrofluidik zum Einsatz kommen. FluxergyWorks ermöglicht es Organisationen, bis zu 256 Fluxergy-Analysatoren für eine zentralisierte Datenauswertung über die Cloud miteinander zu verbinden.
Bitte besuchen Sie fluxergy.com für weitere Informationen.
Kontakt: Dr. Ali Tinazli, atinazli@fluxergy.com
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Das Fluxergy-Diagnosetestsystem besteht aus der Fluxergy Card, einer Einweg-Lab-on-Chip"-Testkassette für Verbrauchsmaterial; dem Fluxergy Analyzer, der den Testprozess durchführt, und der FluxergyWorks-Software, die vom Kliniker/Bediener zur Überprüfung und Interpretation der Testdaten verwendet wird. Die Fluxergy-Karten sind so konzipiert, dass sie sehr kosteneffektiv und skalierbar sind, wobei proprietäre Technologien zur Herstellung von Leiterplatten (PCB) und Mikrofluidik zum Einsatz kommen. FluxergyWorks ermöglicht es Organisationen, bis zu 256 Fluxergy-Analysatoren für eine zentralisierte Datenauswertung über die Cloud miteinander zu verbinden.
Bitte besuchen Sie fluxergy.com für weitere Informationen.
Kontakt: Dr. Ali Tinazli, atinazli@fluxergy.com
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Unternehmensdaten
Anzahl der Beschäftigten50-99
Gründungsjahr2013
Geschäftsfelder- Bildgebung und Diagnostik / Medizinische Ausrüstung und Geräte
- Laborausstattung
- Diagnostika